KLRSHIGH SIGNALOPERATIONAL10-K

KLRS completed a transformative merger with AlloVir, changing from AlloVir's antiviral focus to Kalaris's retinal disease pipeline while showing dramatically improved operating metrics despite increased liabilities.

The merger fundamentally altered the company's business model, moving from antiviral therapeutics to retinal disease treatments, which represents a complete strategic pivot that investors must reassess. The substantial increase in total liabilities (+719%) alongside improved operating performance suggests the merger brought both new obligations and a more efficient operational structure.

Comparing 2026-03-17 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

The merger created a mixed financial picture with concerning liability growth (total liabilities surged 719% to $42.9M) and reduced stockholder equity (down 30% to $78.8M), while operational metrics showed marked improvement with operating losses narrowing 29% and R&D expenses appropriately increasing 149% to support the new retinal disease focus. Despite a 17% decline in cash to $98.1M, the 43% improvement in operating cash flow burn suggests better capital efficiency post-merger. The overall picture indicates a capital-intensive transformation that has improved operational efficiency but increased financial complexity and risk.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+719.3%
$5.2M→$42.9M

Liabilities grew 719.3% — significant increase in debt or obligations, assess impact on financial flexibility.

Capital Expenditure
Cash Flow
+669.2%
$26K→$200K

Capital expenditure jumped 669.2% — major investment cycle underway; assess returns on deployment.

R&D Expense
P&L
+149.2%
$12.3M→$30.8M

R&D investment increased 149.2% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
+85.4%
$5.2M→$9.7M

Current liabilities surged 85.4% — significant near-term obligations; verify ability to meet short-term debt.

Interest Expense
P&L
-46.6%
$2.7M→$1.4M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
+43.3%
-$67.7M→-$38.4M

Operating cash flow surged 43.3% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
-30.4%
$113.3M→$78.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+29.5%
-$65.4M→-$46.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+26.1%
-$58.8M→-$43.4M

Net income grew 26.1% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-17.1%
$118.3M→$98.1M

Cash decreased 17.1% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-07
ADDED
As of March 10, 2026 , the Registrant had 22,928,303 shares of common stock, $0.0001 par value per share, outstanding.
Form 10-K Summary 126 Signatures 127 On March 18, 2025, AlloVir, Inc., a Delaware corporation and our predecessor company, consummated the previously announced merger (the Merger ) pursuant to the terms of the Agreement and Plan of Merger, dated as of November 7, 2024 (the Merger Agreement ), by and among AlloVir, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of AlloVir ( Merger Sub ) and Kalaris Tx, Inc.
(formerly Kalaris Therapeutics, Inc.), a Delaware corporation ( Legacy Kalaris ).
In connection with the completion of the Merger, we changed our name from AlloVir, Inc.
to Kalaris Therapeutics, Inc., and our business became primarily the business conducted by Legacy Kalaris.
+7 more — sign up free →
REMOVED
Exhibits, Financial Statement Schedules 125 Item 16 Form 10-K Summary 127 i Special Note On January 15, 2025, we effected a 1-for-23 reverse stock split of our common stock either issued and outstanding or held as treasury stock.
As a result of the reverse stock split, every 23 shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share.
Stockholders who would otherwise have been entitled to receive fractional shares as a result of the reverse stock split were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of our common stock (as adjusted for the reverse stock split) on The Nasdaq Capital Market on January 15, 2025, the last trading day immediately preceding the effective time of the reverse stock split.
Unless otherwise indicated, all historical share and per share amounts in this Annual Report on Form 10-K have been adjusted to reflect the reverse stock split.
1 Summary of Material Risks Associated with Our Business Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled Risk Factors.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →